Official Twitter for Genentech. See our community guidelines here: ow.ly/1sSw30lmszz
Joined September 2008
- Tweets 7,805
- Following 226
- Followers 123,365
- Likes 2,323
843 Photos and videos
Jun 11
#Breaking: @US_FDA accepted our supplemental Biologics License Application (sBLA) and granted Priority Review for an investigational adjuvant combination regimen in a certain type of stage III colon cancer: gene.com/media/press-release…
2
2
6
1,815
Jun 2
#Breaking: @US_FDA accepted the New Drug Application, under Priority Review, for our investigational oral selective estrogen receptor degrader (SERD) as a treatment for adults with ER , HER2-, early-stage breast cancer. Learn more: gene.com/media/press-release…
4
1,702
Jun 1
#Breaking: We are presenting data at the upcoming #ADASciSessions from our obesity portfolio, highlighting our differentiated approaches to addressing unmet needs for people living with #obesity. Learn more: gene.com/media/press-release…
4
1,460
May 19
#Breaking: We’re presenting new data across breast, lung, gastrointestinal, bladder and blood cancers at the American Society of Clinical Oncology (#ASCO26). Learn more about our efforts to transform cancer care: gene.com/media/press-release…
2
2
1,953
May 15
#Breaking: @US_FDA approved our immunotherapy as an adjuvant treatment option for adults with muscle-invasive bladder cancer (#MIBC) after surgery (cystectomy) who have circulating tumor DNA (ctDNA) molecular residual disease. Learn more: gene.com/media/press-release…
1
6
1,985
Apr 30
At the Association for Research in Vision and Ophthalmology Annual Meeting, we’re sharing key real-world, product and pipeline data from our ophthalmology portfolio. Learn more: gene.com/media/press-release… #ARVO2026
3
1,260
Apr 24
Launching today, All Eyes on DME is our new campaign highlighting diabetic macular edema (DME), an often overlooked eye condition linked to diabetes. Learn more: gene.com/media/press-release…
1
1,099
Apr 21
#Breaking: At the 2026 AAN Annual Meeting (#AANAM), we unveiled positive comprehensive results from our Phase III trials evaluating our investigational BTK inhibitor (BTKi) in people living with relapsing multiple sclerosis (RMS). Learn more: gene.com/media/press-release…
1
1
4
1,178
Apr 21
#Breaking: At #AANAM, we announced positive results from our Phase III study in myelin oligodendrocyte glycoprotein antibody disease (MOGAD). Learn more: gene.com/media/press-release…
4
1,271
Apr 21
#Breaking: The @US_FDA accepted our supplemental Biologics License Application for our medicine to treat systemic lupus erythematosus (SLE), the most common form of #lupus, based on positive Phase III data.
If approved, it would be the first therapy to directly target B cells in SLE. Learn more: [gene.com/media/press-release…]
2
7
1,869
Mar 6
#Breaking: Today meaningful data from our Phase III study in systemic lupus erythematosus was published in @NEJM. Learn more: gene.com/media/press-release…
4
1
10
2,461
Mar 5
#Breaking: Positive Phase II results for our investigational long‑acting amylin analog with Zealand Pharma mark an important step forward as we move from a one‑size‑fits‑all approach to more tailored options for people living with #obesity. gene.com/media/press-release…
1
2
8
1,867
Mar 2
#Breaking: Today we announced positive additional Phase III clinical results of our investigational BTK inhibitor in people living with relapsing multiple sclerosis (RMS).
Learn more: gene.com/media/press-release…
3
2
7
1,842
Feb 20
#Breaking: @US_FDA approved our new combination regimen as the first and only all-oral, fixed-duration treatment for previously untreated adults with chronic lymphocytic leukemia (CLL). Learn more: gene.com/media/press-release…
1
3
6
1,839
Feb 20
#Breaking: @US_FDA accepts New Drug Application for our investigational oral therapy in ER advanced #BreastCancer.
Learn more: gene.com/media/press-release…
1
2
2
1,085
Feb 16
#Breaking: Today we announced positive Phase III data in primary membranous nephropathy. Learn more: gene.com/media/press-release…
1
11
2,103
Feb 7
#Breaking: At the #ACTRIMSForum, we revealed the full results from our Phase III clinical study of our investigational BTK inhibitor (BTKi) in primary progressive multiple sclerosis (PPMS).
Read more: gene.com/media/press-release…
1
1
11
2,012
Jan 27
#Breaking: Today we announced positive Phase II results for our dual GLP-1/GIP receptor agonist for people living with #obesity. Learn more: gene.com/media/press-release…
7
2,074
Jan 20
#Breaking: Today, we announced an expansion of our investment in Holly Springs, NC, to approximately $2B. This investment supports the production of next-generation medicines for metabolic disorders, including obesity. We’re proud to be part of North Carolina’s growing biotech ecosystem. gene.com/media/press-release…
1
7
11
3,110
22 Dec 2025
#Breaking: The @US_FDA approved our new subcutaneous formulation for the treatment of third-line or later relapsed or refractory follicular lymphoma (FL). Learn more about how we’re developing patient-centered solutions: gene.com/media/press-release…
3
1
7
1,727